{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:34Z","timestamp":1763337634185,"version":"3.45.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A640323"],"award-info":[{"award-number":["N42A640323"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Data on risk factors for new-onset atrial fibrillation (NOAF) in hypertensive Asian populations are limited. This study aimed to identify predictors of NOAF in Thai adults with hypertension (HTN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of adults (\u226518 years) newly diagnosed with HTN at Ramathibodi Hospital, Bangkok, from 2010 to 2023. Patients with prior AF or predisposing conditions (e.g., valvular disease and hyperthyroidism) were excluded. Baseline demographics, comorbidities, and medication use were analyzed as time-varying covariates using multivariable Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 293,798 hypertensive patients, 168,441 met the criteria. Over a median follow-up of 3.7 years, 5,028 developed NOAF (5.7 per 1,000 person-years). A significant interaction between age and body mass index (BMI) was observed. In patients &amp;lt;60 years, low BMI increased NOAF risk (HR: 2.3; 95% CI: 1.4\u20133.6), while overweight and obesity did not. In those \u226560\u201379 years, NOAF risk increased 2- to 3-fold in underweight, overweight, and obese individuals compared to normal BMI. In patients \u226580 years, the risk was 3- to 4-fold higher across all BMI categories. Male sex and comorbidities (vascular disease, stroke, heart failure, chronic kidney disease, and hyperuricemia) were associated with a 1.2\u20131.8-fold increased risk. Statin use reduced NOAF risk (HR: 0.8; 95% CI: 0.7\u20130.9), while SGLT2 inhibitors and GLP-1 receptor agonists showed a non-significant protective trend (HR: 0.8; 95% CI: 0.7\u20131.1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In Thai hypertensive patients, older age, male sex, abnormal BMI, and comorbidities predict NOAF, while statin use may be protective. Further prospective studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpaf149","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:05:00Z","timestamp":1754654700000},"page":"1076-1087","source":"Crossref","is-referenced-by-count":0,"title":["Factors Associated With New-Onset Atrial Fibrillation in Thai Adults with Hypertension"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0528-0227","authenticated-orcid":false,"given":"Varisa","family":"Limpijankit","sequence":"first","affiliation":[{"name":"Chulalongkorn University International Medical Program, The Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thinnakrit","family":"Sasiprapha","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Htun","family":"Teza","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuchate","family":"Pattanateepapon","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukanya","family":"Siriyotha","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suparee","family":"Boonmanunt","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-1308","authenticated-orcid":false,"given":"John","family":"Attia","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, and Hunter Medical Research Institute , New Lambton, NSW ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-386X","authenticated-orcid":false,"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"2025111618571753100_CIT0001","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025111618571753100_CIT0002","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"volume-title":"Hypertension World Health Organization Newsroom","year":"2023","author":"World Health Organization","key":"2025111618571753100_CIT0003"},{"key":"2025111618571753100_CIT0004","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.35755\/jmedassocthai.2021.10.12199","article-title":"2019 Thai guidelines on the treatment of hypertension: executive summary","volume":"104","author":"Kunanon","year":"2021","journal-title":"J Med Assoc Thai"},{"volume-title":"Hypertension Care in Thailand: best practices and challenges, 2019","year":"2019","author":"World Health Organization","key":"2025111618571753100_CIT0005"},{"key":"2025111618571753100_CIT0006","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10654-022-00914-0","article-title":"Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies","volume":"38","author":"Aune","year":"2023","journal-title":"Eur J Epidemiol"},{"key":"2025111618571753100_CIT0007","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.120.16659","article-title":"Hypertension burden and the risk of new-onset atrial fibrillation: a nationwide population-based study","volume":"77","author":"Lee","year":"2021","journal-title":"Hypertension"},{"key":"2025111618571753100_CIT0008","doi-asserted-by":"publisher","first-page":"9G","DOI":"10.1016\/S0002-9149(03)00227-3","article-title":"Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target","volume":"91","author":"Healey","year":"2003","journal-title":"Am J Cardiol"},{"key":"2025111618571753100_CIT0009","doi-asserted-by":"publisher","first-page":"228","DOI":"10.14797\/mdcj-11-4-228","article-title":"Atrial fibrillation and hypertension: mechanistic, epidemiologic, and treatment parallels","volume":"11","author":"Ogunsua","year":"2015","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"2025111618571753100_CIT0010","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","article-title":"Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies","volume":"122","author":"Verdecchia","year":"2018","journal-title":"Circ Res"},{"key":"2025111618571753100_CIT0011","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/hr.2011.39","article-title":"Oxidative stress and endothelial dysfunction in hypertension","volume":"34","author":"Schulz","year":"2011","journal-title":"Hypertens Res"},{"key":"2025111618571753100_CIT0012","doi-asserted-by":"publisher","first-page":"862164","DOI":"10.3389\/fphys.2022.862164","article-title":"Role of inflammation in the pathogenesis of atrial fibrillation","volume":"13","author":"Ihara","year":"2022","journal-title":"Front Physiol"},{"key":"2025111618571753100_CIT0013","doi-asserted-by":"publisher","first-page":"8423","DOI":"10.18632\/aging.103149","article-title":"Inflammatory activation and endothelial dysfunction markers in patients with permanent atrial fibrillation: a cross-sectional study","volume":"12","author":"Maida","year":"2020","journal-title":"Aging (Milano)"},{"key":"2025111618571753100_CIT0014","doi-asserted-by":"publisher","first-page":"457","DOI":"10.21037\/atm.2017.10.33","article-title":"Hypertension associated with atrial fibrillation","volume":"5","author":"Aronow","year":"2017","journal-title":"Ann Transl Med"},{"key":"2025111618571753100_CIT0015","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2025111618571753100_CIT0016","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/08037051.2019.1633905","article-title":"Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study","volume":"28","author":"Larstorp","year":"2019","journal-title":"Blood Press"},{"key":"2025111618571753100_CIT0017","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0140-6736(09)60443-8","article-title":"Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study","volume":"373","author":"Schnabel","year":"2009","journal-title":"Lancet"},{"key":"2025111618571753100_CIT0018","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2010.08.049","article-title":"A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk In Communities [ARIC] Study)","volume":"107","author":"Chamberlain","year":"2011","journal-title":"Am J Cardiol"},{"key":"2025111618571753100_CIT0019","doi-asserted-by":"publisher","first-page":"e000102","DOI":"10.1161\/JAHA.112.000102","article-title":"Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF Consortium","volume":"2","author":"Alonso","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2025111618571753100_CIT0020","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1038\/s41598-020-61437-w","article-title":"A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project)","volume":"10","author":"Orozco-Beltran","year":"2020","journal-title":"Sci Rep"},{"key":"2025111618571753100_CIT0021","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.chest.2018.09.011","article-title":"A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects","volume":"155","author":"Li","year":"2019","journal-title":"Chest"},{"key":"2025111618571753100_CIT0022","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12872-016-0232-4","article-title":"Prevalence and associating factors of atrial fibrillation in patients with hypertension: a nation-wide study","volume":"16","author":"Krittayaphong","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2025111618571753100_CIT0023","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.imu.2023.101285","article-title":"Retinopathy prediction in type 2 diabetes: time-varying Cox proportional hazards and machine learning models","volume":"40","author":"Looareesuwan","year":"2023","journal-title":"Inf Med Unlocked"},{"key":"2025111618571753100_CIT0024","doi-asserted-by":"publisher","first-page":"e50627","DOI":"10.2196\/50627","article-title":"Application of dragonnet and conformal inference for estimating individualized treatment effects for personalized stroke prevention: retrospective cohort study","volume":"9","author":"Lolak","year":"2025","journal-title":"JMIR Cardio"},{"key":"2025111618571753100_CIT0025","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/europace\/eus333","article-title":"Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients","volume":"15","author":"Wilke","year":"2013","journal-title":"Europace"},{"key":"2025111618571753100_CIT0026","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1093\/eurheartj\/ehad375","article-title":"New-onset atrial fibrillation prediction: the HARMS2-AF risk score","volume":"44","author":"Segan","year":"2023","journal-title":"Eur Heart J"},{"key":"2025111618571753100_CIT0027","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1016\/j.hrthm.2025.02.013","article-title":"Racial differences and similarities in atrial fibrillation epidemiology and risk factors in UK Biobank and Korean NHIS-HEALS cohort studies","volume":"22","author":"Kim","year":"2025","journal-title":"Heart Rhythm"},{"key":"2025111618571753100_CIT0028","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1055\/a-2278-8769","article-title":"Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study","volume":"124","author":"Kang","year":"2024","journal-title":"Thromb Haemost"},{"key":"2025111618571753100_CIT0029","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"key":"2025111618571753100_CIT0030","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.hrthm.2007.07.023","article-title":"Atrial fibrillation in the elderly: mechanisms and management","volume":"4","author":"Curtis","year":"2007","journal-title":"Heart Rhythm"},{"key":"2025111618571753100_CIT0031","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2174\/1573403X15666181205110624","article-title":"Gender differences in atrial fibrillation: a review of epidemiology, management, and outcomes","volume":"15","author":"Westerman","year":"2019","journal-title":"Curr Cardiol Rev"},{"key":"2025111618571753100_CIT0032","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.amjmed.2016.02.029","article-title":"Usefulness of CHADS2 and CHA2DS2-VASc Scores in the prediction of new-onset atrial fibrillation: a population-based study","volume":"129","author":"Saliba","year":"2016","journal-title":"Am J Med"},{"key":"2025111618571753100_CIT0033","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjopen\/oeac046","article-title":"Changes in the CHA2DS2-VASC score as a predictor of incident atrial fibrillation in older Chinese individuals: the AF-CATCH study","volume":"2","author":"Zhang","year":"2022","journal-title":"Eur Heart J Open"},{"key":"2025111618571753100_CIT0034","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1097\/HJH.0b013e32833a7dfe","article-title":"Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients","volume":"28","author":"Horio","year":"2010","journal-title":"J Hypertens"},{"key":"2025111618571753100_CIT0035","doi-asserted-by":"publisher","first-page":"8172639","DOI":"10.1155\/2022\/8172639","article-title":"Hyperuricemia increases the risk of atrial fibrillation: a systematic review and meta-analysis","volume":"2022","author":"Gao","year":"2022","journal-title":"Int J Endocrinol"},{"key":"2025111618571753100_CIT0036","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2016.04.007","article-title":"Atrial fibrillation in chronic kidney disease","volume":"33","author":"Voroneanu","year":"2016","journal-title":"Eur J Intern Med"},{"key":"2025111618571753100_CIT0037","doi-asserted-by":"publisher","first-page":"641136","DOI":"10.3389\/fcvm.2021.641136","article-title":"The key role of uric acid in oxidative stress, inflammation, fibrosis, apoptosis, and immunity in the pathogenesis of atrial fibrillation","volume":"8","author":"Deng","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025111618571753100_CIT0038","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/hr.2014.104","article-title":"Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: a longitudinal cohort study","volume":"37","author":"Jong","year":"2014","journal-title":"Hypertens Res"},{"key":"2025111618571753100_CIT0039","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.jacc.2009.08.020","article-title":"Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)","volume":"54","author":"Haywood","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025111618571753100_CIT0040","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2025111618571753100_CIT0041","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.120.14766","article-title":"Effect of intensive blood pressure lowering on the risk of atrial fibrillation","volume":"75","author":"Soliman","year":"2020","journal-title":"Hypertension"},{"key":"2025111618571753100_CIT0042","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2125.2012.04258.x","article-title":"The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"74","author":"Fang","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2025111618571753100_CIT0043","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijcard.2007.07.137","article-title":"Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies","volume":"126","author":"Liu","year":"2008","journal-title":"Int J Cardiol"},{"key":"2025111618571753100_CIT0044","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/VHRM.S4841","article-title":"Pleiotropic effects of statins in atrial fibrillation patients: the evidence","volume":"5","author":"Hadi","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"2025111618571753100_CIT0045","doi-asserted-by":"publisher","first-page":"e0186972","DOI":"10.1371\/journal.pone.0186972","article-title":"Statins and new-onset atrial fibrillation in a cohort of patients with hypertension. Analysis of electronic health records, 2006\u20132015","volume":"12","author":"Alves-Cabratosa","year":"2017","journal-title":"PLoS One"},{"key":"2025111618571753100_CIT0046","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.ijcard.2012.11.087","article-title":"Dosage of statin, cardiovascular comorbidities, and risk of atrial fibrillation: a nationwide population-based cohort study","volume":"168","author":"Hung","year":"2013","journal-title":"Int J Cardiol"},{"key":"2025111618571753100_CIT0047","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MJT.0b013e31827ab488","article-title":"Statin use and risk of atrial fibrillation or flutter: a population-based case-control study","volume":"22","author":"Veronese","year":"2015","journal-title":"Am J Ther"},{"key":"2025111618571753100_CIT0048","doi-asserted-by":"publisher","first-page":"e035827","DOI":"10.1161\/JAHA.124.035827","article-title":"Long-term statin use is associated with reduced rates of adverse events in patients with newly diagnosed atrial fibrillation","volume":"13","author":"Huang","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025111618571753100_CIT0049","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2025111618571753100_CIT0050","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.hrtlng.2023.02.009","article-title":"SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: a meta-analysis of randomized controlled trials","volume":"59","author":"He","year":"2023","journal-title":"Heart Lung"},{"key":"2025111618571753100_CIT0051","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025111618571753100_CIT0052","doi-asserted-by":"publisher","first-page":"915455","DOI":"10.3389\/fcvm.2022.915455","article-title":"Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: a mini review","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025111618571753100_CIT0053","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacbts.2023.01.005","article-title":"Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice","volume":"8","author":"Bohne","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"2025111618571753100_CIT0054","doi-asserted-by":"publisher","first-page":"e022222","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025111618571753100_CIT0055","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium\u2013glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025111618571753100_CIT0056","doi-asserted-by":"publisher","first-page":"e14292","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis","volume":"54","author":"Saglietto","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2025111618571753100_CIT0057","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","article-title":"Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise","volume":"70","author":"Lavie","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025111618571753100_CIT0058","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/eurheartj\/ehw045","article-title":"Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions","volume":"38","author":"Wong","year":"2017","journal-title":"Eur Heart J"},{"key":"2025111618571753100_CIT0059","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijcard.2016.04.036","article-title":"Underweight is a risk factor for atrial fibrillation: a nationwide population-based study","volume":"215","author":"Kang","year":"2016","journal-title":"Int J Cardiol"},{"key":"2025111618571753100_CIT0060","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12933-021-01415-2","article-title":"Underweight is a major risk factor for atrial fibrillation in Asian people with type 2 diabetes mellitus","volume":"20","author":"Hsu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025111618571753100_CIT0061","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ebiom.2018.08.034","article-title":"A U-shaped relationship of body mass index on atrial fibrillation recurrence post ablation: a report from the Guangzhou atrial fibrillation ablation registry","volume":"35","author":"Deng","year":"2018","journal-title":"EBioMedicine"},{"key":"2025111618571753100_CIT0062","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY)","volume":"65","author":"Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025111618571753100_CIT0063","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4172\/2167-0277.1000282","article-title":"Obstructive sleep apnea as a risk factor for atrial fibrillation: a meta-analysis","volume":"7","author":"Youssef","year":"2018","journal-title":"J Sleep Disord Ther"},{"key":"2025111618571753100_CIT0064","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamacardio.2018.0095","article-title":"Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review","volume":"3","author":"Linz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025111618571753100_CIT0065","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jacep.2015.02.014","article-title":"Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis","volume":"1","author":"Shukla","year":"2015","journal-title":"JACC Clin Electrophysiol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf149\/64023709\/hpaf149.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/12\/1076\/64023709\/hpaf149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/12\/1076\/64023709\/hpaf149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T23:57:23Z","timestamp":1763337443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/38\/12\/1076\/8232071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,8,9]]},"published-print":{"date-parts":[[2025,11,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf149","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"type":"print","value":"0895-7061"},{"type":"electronic","value":"1941-7225"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,9]]}}}